Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Weighted Average and Diluted): 2020-2025

Historic EPS (Weighted Average and Diluted) for Spyre Therapeutics (SYRE) over the last 5 years, with Sep 2025 value amounting to -$0.15.

  • Spyre Therapeutics' EPS (Weighted Average and Diluted) rose 99.64% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.77, marking a year-over-year increase of 95.03%. This contributed to the annual value of -$127.21 for FY2024, which is 76.88% up from last year.
  • Spyre Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.15 in Q3 2025, which was down 100.66% from $22.86 recorded in Q2 2025.
  • Spyre Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $40.14 during Q2 2023, with a 5-year trough of -$564.94 in Q4 2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$59.67, with a median of -$23.61 in 2024.
  • Data for Spyre Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increase of 14,966.67% (in 2023) and a maximum YoY decrease of 11,945.63% (in 2023) over the last 5 years.
  • Over the past 5 years, Spyre Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$24.33 in 2021, then surged by 80.72% to -$4.69 in 2022, then tumbled by 11,945.63% to -$564.94 in 2023, then soared by 94.42% to -$31.53 in 2024, then spiked by 99.64% to -$0.15 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.15 in Q3 2025, compared to $22.86 in Q2 2025 and -$23.95 in Q1 2025.